Nasus Pharma Ltd. · AMEX:NSRX
Nasus Pharma — Investor Presentation (February 2026)
67 slides from Nasus Pharma's investor presentation, Feb 26, 2026
Slide 1: A New Frontier in Intranasal Drug Delivery
Please migrate color palette to match website A NEW FRONTIER IN INTRANASAL DRUG DELIVERY A clinical-stage pharmaceutical company leveraging its proprietary powder-based intranasal technology to develop innovative intranasal products Ticker NSRX Exchange NYSE American Company Presentation – February
Slide 2: Forward Looking Statements; Disclaimer
Forward Looking Statements; Disclaimer This presentation of Nasus Pharma Ltd. (the “Company”, “Nasus” or “Nasus Pharma”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities law. Words such as “expects,” “intends,” “pla
Slide 3: Company Highlights
Company Highlights Nasus is Uniquely Positioned to Transform Care via Intranasal Drug Delivery NS002 was designed to address Proprietary Nasax powder Use of well-known active limitations of injectable technology aims to enhance pharmaceutical ingredients Epinephrine, with a needle-free, intranasal d
Slide 4: Robust Asset Pipeline Setting Up Potential for Long Term Growth
Robust Asset Pipeline Setting Up Potential for Long Term Growth Transforming Care via Intranasal Drug Delivery Drug Candidate Molecule Indication Preclinical Phase 1 Phase 2 Pivotal Trial Next Milestone Pivotal study NS002 Epinephrine Anaphylaxis Phase 2 repeat dose PK study interim results reported
Slide 5: Proprietary Nasax Platform Enables Superior Drug Absorption
Proprietary Nasax Platform Enables Superior Drug Absorption Powder formulation can reach all parts of nasal cavity; The greater intranasal absorption area enables faster delivery and higher maximal drug concentration compared to liquid formulations Liquid formulation Powder formulation Liquid Spray
Slide 6: NS002: Intranasal Epinephrine
NS002: INTRANASAL EPINEPHRINE
Slide 7: Anaphylaxis: A Time-Critical Medical Emergency
Anaphylaxis: A Time-Critical Medical Emergency Anaphylaxis is a severe allergic reaction; fatal in ~1% of cases1 The standard of care for anaphylaxis is Epinephrine – this is typically self-administered via an Epinephrine auto-injector (EAI) or given via intramuscular (IM) injection by a healthcare
Slide 8: NS002 Designed to Address the Limitations of Intramuscular Epinephrine
NS002 Designed to Address the Limitations of Intramuscular Epinephrine The proposed solution: NS002 Autoinjectors1 with a 12-18 month Product candidate aims to offer shelf-life a needle-free solution, longer shelf-life, easily administered Large and bulky to carry2 15cm by trained professionals and
Slide 9: Anaphylaxis: A Growing Opportunity in a Large Market
Anaphylaxis: A Growing Opportunity in a Large Market Estimated prevalence of anaphylaxis ~1-3% among the global population1 ~$2.3B Global Epinephrine market in 20242 ~40M Patients with type 1 allergies in the U.S.3 +6.5% From 2010 to 20233 CAGR Patients experience severe type I ~20M allergic reactio
Slide 10: NS002: Clear Roadmap to NDA
NS002: Clear Roadmap to NDA • Following FDA guidance based on the 505(b)(2) regulatory pathway • Demonstration of comparable PK/PD to EpiPen® only requirement for regulatory approval • Pivotal trial expected to initiate Q4 2026 • Short and cost-effective clinical development NP007: NS002 Initiate NS
Slide 11: The Competitive Landscape Indicates a Large and Expanding Opportunity for Needle-Free Epinephrine
The Competitive Landscape Indicates a Large and Expanding Opportunity for Needle-Free Epinephrine Nasus Pharma5 2 3 Orexo Aquestive ARS Pharma1 (Market Cap $64M*) (Market Cap (Market Cap (Market Cap $1.05B*) NS002 SEK1.15B*) $403.8M*) EpiPen®4 PK Parameters Neffy (nasal spray) (nasal powder) OX640 A
Slide 12: Market Research Shows Onset of Action is Important to Allergists
Market Research* Shows Onset of Action is Important to Allergists Speed of onset overwhelmingly Time to reach maximum epinephrine concentration Time to therapeutic epinephrine threshold is important to physicians prescribing an impacts caregivers’ recommendation of epinephrine highly clinically mean
Slide 13: NS002: NP007 Phase 2 Repeated Dose and Nasal Allergic Challenge Study
NS002: NP007: PHASE 2 REPEATED DOSE AND NASAL ALLERGIC CHALLENGE STUDY
Slide 14: Study NP007: Designed to Compare Bioavailability, PK, PD and Safety
Study NP007: Designed to Compare Bioavailability, PK, PD and Safety of Single and Repeat Dosing with and without Nasal Allergic Challenge (NAC) Interim analysis Week 7: Week 5: Nasal allergic 2xNS002 4mg 2w washout challenge L+L nostril 2xNS002 4mg Week 1: L+L nostril Group 1 Nasal allergic Week 2:
Slide 15: Study NP007 Strengthens NS002's Potential to be Best in Class
Study NP007 Strengthens NS002’s Potential to be Best in Class 1 Phase 2 repeat dose study validates former PK and safety findings, further demonstrating attributes of nasal powder technology: Rapid and high delivery of epinephrine required in anaphylaxis. NS002 demonstrated faster absorption: 2 • Sh
Slide 16: Faster, Higher and Sustained Absorption in Critical Therapeutic Window
Faster, Higher and Sustained Absorption in Critical Therapeutic Window Single dose results: Geometric mean +SE, 0.5hr 600 Plasma epinephrine concentration (pg/mL) 500 400 300 200 A. NAC + IN spray 100 B. EpiPen C. IN spray, normal conditions 0 0 5 10 15 20 25 30 Time (min.) 16
Slide 17: NS002 Demonstrates Favorable PK vs. EpiPen
NS002 Demonstrates Favorable PK vs. EpiPen® Geometric mean plasma epinephrine concentration over time: NP007 Ph2 interim analysis 500 Plasma Eipnephrine (pg/mL) Nasus (4mg) x1 450 NAC+ Nasus (4mg) x1 400 EpiPen x1 350 300 250 200 150 100 50 0 0 5 10 15 20 25 30 35 40 45 50 55 60 Time (min.) 17
Slide 18: Neffy PK vs. EpiPen
Neffy® PK vs. EpiPen®* Neffy®’s Published Pharmacokinetic Data from FDA Approval Materials** * The pharmacokinetic information presented above is based solely on publicly available data from the Neffy® FDA approval package. The Company has not conducted any head-to-head clinical trials comparing NS0
Slide 19: NS002 Single Dose vs. EpiPen: Higher Cmax, Shorter Tmax and T100
NS002 Single Dose vs. EpiPen® : Higher Cmax, Shorter Tmax and T100 Cmax (pg/mL) Tmax (min.) T100 (min.) Geometric mean median median 900 16 3.5 15 800 3.01 14 3 700 654.58 12 10.8 2.5 600 547.52 505.03 10 Cmax (pg/mL) Time (min.) Time (min.) 500 2 8 400 1.5 6 300 1 4.2 1 4 200 0.53 2 0.5 100 0 0 0 A
Slide 20: More Subjects Achieved Epinephrine Threshold with NS002 compared to EpiPen
More Subjects Achieved Epinephrine Threshold with NS002 compared to EpiPen® Proportion (%) who reached 100pg/mL 110 100 95.7 95.7 96.3 95.7 91.3 92.6 92.6 88.9 90 Proprtion reached 100pg/mL (%) 87.5 87.5 80 77.8 83.3 70 60.9 66.7 60 50 40 30 33.3 20 10 0 0 2.5 5 7.5 10 15 Time (min.) A. NAC + IN spr
Slide 21: Subject Achieving Epinephrine Threshold with Neffy
Subject Achieving Epinephrine Threshold with Neffy* Time to reach 100 pg/mL (minutes) median Single dose Double dose ARS “Neffy" ARS “Neffy*" x2 9 7-9 Subjects who reached 100 pg/ml within 60 minutes Single dose Double dose Time ARS “Neffy*" x2 ARS “Neffy*" (minutes) L/R R/R 5 18% 25% 20% 10 55% 55%
Slide 22: NS002 Pharmacodynamic Response Tracks EpiPen and Kept Within Normal Limits
NS002 Pharmacodynamic Response Tracks EpiPen® and Kept Within Normal Limits Median change from baseline - Systolic blood pressure (Single dose) 20 15 A. NAC+ Nasus 4mg B. EpiPen C. Nasus 4mg Baseline mm Hg (median): Median change (mm Hg) 10 NAC+Nasus x1 EpiPen Nasus x1 5 0 119 114 114 0 20 40 60 80
Slide 23: NS002 Pharmacodynamic Response Tracks EpiPen Cont.
NS002 Pharmacodynamic Response Tracks EpiPen® and Kept Within Normal Limits Cont. Median change from baseline- Heart rate (Single dose) 20 A. NAC+ Nasus 4mg B. EpiPen C. Nasus 4mg Baseline BPM (median): HR Median change (BPM) 15 10 NAC+Nasus x1 EpiPen Nasus x1 5 0 76 75 73 0 20 40 60 80 100 120 -5 -
Slide 24: Repeat Dosing Continues to Demonstrate Faster, Higher and Sustained Absorption
Repeat Dosing Continues to Demonstrate Faster, Higher and Sustained Absorption in a Dose Proportional Manner Normal conditions: NAC conditions: Geometric mean+SE, 0.5hr Geometric mean+SE, 0.5hr 1200 1000 D. EpiPen * 2 (L/R) D. EpiPen * 2 (L/R) 900 E1. IN * 2 (L/L), normal conditions 1000 F1. NAC + I
Slide 25: NS002 Repeated Dosing vs. EpiPen: Higher Cmax, Shorter Tmax and T100
NS002 Repeated Dosing vs. EpiPen©: Higher Cmax, Shorter Tmax and T100 Cmax (pg/mL) Tmax (min.) Geometric mean median 1400 25 1200 1087.93 20 19.2 19.2 1000 923.13 16.8 879.26 15.6 831.47 817.32 Cmax (pg/mL) Time (min.) 15 13.2 800 600 10 400 5 200 0 0 D. EpiPen * 2 (L/R) E1. IN * 2 (L/L), E2. IN * 2
Slide 26: NS002 Repeat Dosing Tracks EpiPen and Kept Within Normal Limits
NS002 Repeat Dosing Tracks EpiPen® and Kept Within Normal Limits Median change from baseline - Systolic blood pressure (Normal conditions) 30 D. EpiPen x2 (L/R) E1. IN x 2 (L/L) E2. E2. IN x 2 (L/R) normal conditions normal conditions Baseline mm Hg (median): Median change (mm Hg) 20 Nasus x 2 EpiPe
Slide 27: NS002 Repeat Dosing Tracks EpiPen and Kept Within Normal Limits Cont.
NS002 Repeat Dosing Tracks EpiPen® and Kept Within Normal Limits Cont. Median Change from baseline- Diastolic blood pressure (Normal conditions) 30 D. EpiPen x2 (L/R) E1. IN x 2 (L/L) E2. E2. IN x 2 (L/R) Change from baseline (mm Hg) normal conditions normal conditions Baseline mm Hg (median): 20 Na
Slide 28: NS002 Repeat Dosing Tracks EpiPen and Kept Within Normal Limits Cont.
NS002 Repeat Dosing Tracks EpiPen® and Kept Within Normal Limits Cont. Median change from baseline- Heart rate (Normal conditions) 30 D. EpiPen x2 (L/R) E1. IN x 2 (L/L) E2. E2. IN x 2 (L/R) normal conditions normal conditions Baseline BPM (median): HR Median change (BPM) 20 Nasus x 2 EpiPen x2 Nasu
Slide 29: Study NP007 Demonstrates that NS002 is Well Tolerated after Single and Repeat Administration
Study NP007 Demonstrates that NS002 is Well Tolerated after Single and Repeat Administration (50 participants and 421 drug administrations) • No SAEs reported • No CV AEs • Most AEs were local in nature and self resolving, with 95% mild and 5% moderate. • 1 participant discontinued due to eye pain.
Slide 30: Strong Global IP Position
Strong Global IP Position Patent No./ Grant Date/ Country App. No. Filed Status/Next action Expiration date Publication No. Pub. Date PCT PCT/IL2018/050914 19/08/2018 WO 2019/038756 A1 National Phase entered 19/08/2038 Australia 2018319592 19/08/2018 2018319592 10/10/2024 Granted 19/08/2038 Canada 3
Slide 31: Strong Global IP Position
Strong Global IP Position Patent No./ Grant Date/ Country App. No. Filed Status/Next action Expiration date Publication No. Pub. Date USA 62/989,913 16/03/2020 Term Ended 16/03/2040 USA 17/135,528 28/12/2020 11,400,045 02/08/2022 Granted 28/12/2040 PCT PCT/IL2021/050288 16/03/2021 WO 2021/186437 23/
Slide 32: Nasus is Uniquely Positioned to Transform Care via Intranasal Delivery
Proprietary Nasax powder technology designed to enhance intranasal drug absorption Lead product candidate NS002 is needle-free, convenient, and easily administered; aiming to offer an alternative to Epinephrine autoinjectors and directly addressing the currently unmet need Multiple Phase 2 studies c
Slide 33: Leadership Team
Leadership Team Udi Gilboa, Co-Founder & Executive Chairman Mr. Gilboa is a prominent serial life sciences entrepreneur and the co-founder of multiple medical device and pharmaceutical companies. He co-founded and served as director and CFO of BioBlast Ltd (NASDAQ: ORPN), Alcobra Ltd (NASDAQ: ADHD),
Slide 34: A New Frontier in Intranasal Drug Delivery
Please migrate color palette to match website A NEW FRONTIER IN INTRANASAL DRUG DELIVERY A clinical-stage pharmaceutical company leveraging its proprietary powder-based intranasal technology to develop innovative intranasal products to treat emergency medical conditions Ticker NSRX Exchange NYSE Ame
Slide 35: NS002: NP002 Pilot Study
NS002: NP002: PILOT STUDY
Slide 36: NP002: NS002 Pilot Study Overview
NP002: NS002 Pilot Study Overview Study goal: Test NS002’s Epinephrine bioavailability following allergenic challenge PK/PD measurements: plasma Epinepherine, Tmax, T100, AUC, SBP, HR 12 healthy adults with allergic rhinitis (9 male, 3 female) Screening: positive to skin allergen test Period 1 Perio
Slide 37: NP002: Faster, Higher and Sustained Absorption in Critical Therapeutic Window
NP002: Faster, Higher and Sustained Absorption in Critical Therapeutic Window Pilot Study Pharmacokinetics (PK) Plasma epinephrine – geometric mean – 60 min. n=12 37
Slide 38: NS002 vs. EpiPen: Shorter Tmax and T100 and Higher Absorption
NS002 vs. EpiPen®: Shorter Tmax and T100 and Higher Absorption Pilot study PK – baseline corrected time medians Area Under Curve Tmax median (min.) n=12 n=12 20.00 16.50 15.00 Tmax (min.) 9.00 8.98 10.00 5.99 5.00 2.50 0.00 EpiPen Nasus 1.6mg Nasus Nasus 3.2mg Nasus 1.6mg+Allergic 3.2mg+Allergic cha
Slide 39: NS002 Pharmacodynamic Response Tracks EpiPen and Kept Within Normal Limits
NS002 Pharmacodynamic Response Tracks EpiPen® and Kept Within Normal Limits Pilot study pharmacodynamics (PD) Systolic Blood Pressure n=12 125 120 SBP (mm Hg) EpiPen 115 Nasus 1.6mg normal condition 110 Nasus 1.6mg allergenic challenge 105 Nasus 3.2mg normal condition Nasus 3.2mg allergenic challeng
Slide 40: NS002: NP006 Phase 2 Single Dose Study
NS002: NP006: PHASE 2 SINGLE DOSE STUDY
Slide 41: NP006: NS002 Phase 2 Study Designed to Assess Safety and Tolerability of Single Dose
NP006: NS002 Phase 2 Study Designed to Assess Safety and Tolerability of Single Dose Administration 1 week 1 week Arm 1: N=6 B C A Nasus spray 3.6mg Nasus spray 4.0mg On each dosing day: EpiPen® in one nostril in one nostril Screening PK sampling: 12 healthy -1 to 2hr. (13 samples) volunteers, age 1
Slide 42: More Subjects Achieved Epinephrine Threshold with NS002 Compared to EpiPen
More Subjects Achieved Epinephrine Threshold with NS002 Compared to EpiPen® NP006 Phase 2 PK results Plasma Epinephrine Results 12 healthy subjects 6min EpiPen® 55 % Nasus 3.6mg 72 % Nasus 4.0mg 91% Proportion of subjects achieving clinical threshold of 100pg/mL at 6min * None of the studies of NS-0
Slide 43: NS002 Single Dose vs. EpiPen: Higher Cmax, Shorter Tmax and T100
NS002 Single Dose vs. EpiPen©: Higher Cmax, Shorter Tmax and T100 Phase 2 Results - Cmax, Tmax and T100pg/mL Tmax (median, minutes) n=12 T100pg/mL (median, minutes) n=12 Cmax (Geometric mean + SD) n=12 1400 16 10 15 9 9 1200 14 8 12 1000 7 Mean Cmax (pg/mL) Median T100 (min.) Median Tmax (min.) 10 1
Slide 44: NS002 Achieved Higher Absorption vs. EpiPen in the Critical Therapeutic Window
NS002 Achieved Higher Absorption vs. EpiPen® in the Critical Therapeutic Window Mean AUC0-4min +SD n=12 Mean AUC0-10min +SD n=12 70 140 60 120 Mean AUC h*pg/mL 50 Mean AUC h*pg/mL 100 40 80 27.44 63.96 30 50.99 60 20 14.17 40 27.38 10 5.85 20 0 0 EpiPen Nasus 3.6mg Nasus 4.0mg EpiPen Nasus 3.6mg Nas
Slide 45: NP006: NS002 Pharmacodynamic Response Tracks EpiPen and Kept Within Normal Limits
NP006: NS002 Pharmacodynamic Response Tracks EpiPen® and Kept Within Normal Limits Heart Rate n=12 Systolic Blood Pressure n=12 140 90 130 85 Systolic BP (mean) Phase 2: 80 HR (mean) 120 PD results 110 75 70 100 65 90 0 20 40 60 80 100 120 0 20 40 60 80 100 120 Time (min.) Time (min.) Respiration Ra
Slide 46: NP006: Results Summary
NP006: Results Summary NS002 Could Be a Compelling Alternative to Epinephrine Autoinjectors, with Faster, Greater and Well-Tolerated Epinephrine Delivery 01 NS002 reached the Epinephrine therapeutic plasma threshold faster than EpiPen® 02 Maximum Epinephrine absorption (Tmax) achieved significantly
Slide 47: NS002: NP007 Phase 2 Repeated Dose and Nasal Allergic Challenge Study
NS002: NP007: PHASE 2 REPEATED DOSE AND NASAL ALLERGIC CHALLENGE STUDY
Slide 48: Study NP007: Designed to Compare Bioavailability, PK, PD and Safety
Study NP007: Designed to Compare Bioavailability, PK, PD and Safety of Single and Repeat Dosing with and without Nasal Allergic Challenge (NAC) Interim analysis Week 7: Week 5: Nasal allergic 2xNS002 4mg 2w washout challenge L+L nostril 2xNS002 4mg Week 1: L+L nostril Group 1 Nasal allergic Week 2:
Slide 49: Study NP007 Strengthens NS002's Potential to be Best in Class
Study NP007 Strengthens NS002’s Potential to be Best in Class 1 Phase 2 repeat dose study validates former PK and safety findings, further demonstrating attributes of nasal powder technology: Rapid and high delivery of epinephrine required in anaphylaxis. NS002 demonstrated faster absorption: 2 • Sh
Slide 50: Faster, Higher and Sustained Absorption in Critical Therapeutic Window
Faster, Higher and Sustained Absorption in Critical Therapeutic Window Single dose results: Geometric mean +SE, 0.5hr 600 Plasma epinephrine concentration (pg/mL) 500 400 300 200 A. NAC + IN spray 100 B. EpiPen C. IN spray, normal conditions 0 0 5 10 15 20 25 30 Time (min.) 50
Slide 51: NS002 Demonstrates Favorable PK vs. EpiPen
NS002 Demonstrates Favorable PK vs. EpiPen® Geometric mean plasma epinephrine concentration over time: NP007 Ph2 interim analysis 500 Plasma Eipnephrine (pg/mL) Nasus (4mg) x1 450 NAC+ Nasus (4mg) x1 400 EpiPen x1 350 300 250 200 150 100 50 0 0 5 10 15 20 25 30 35 40 45 50 55 60 Time (min.) 51
Slide 52: Neffy PK vs. EpiPen
Neffy® PK vs. EpiPen®* Neffy®’s Published Pharmacokinetic Data from FDA Approval Materials** * The pharmacokinetic information presented above is based solely on publicly available data from the Neffy® FDA approval package. The Company has not conducted any head-to-head clinical trials comparing NS0
Slide 53: NS002 Single Dose vs. EpiPen: Higher Cmax, Shorter Tmax and T100
NS002 Single Dose vs. EpiPen® : Higher Cmax, Shorter Tmax and T100 Cmax (pg/mL) Tmax (min.) T100 (min.) Geometric mean median median 900 16 3.5 15 800 3.01 14 3 700 654.58 12 10.8 2.5 600 547.52 505.03 10 Cmax (pg/mL) Time (min.) Time (min.) 500 2 8 400 1.5 6 300 1 4.2 1 4 200 0.53 2 0.5 100 0 0 0 A
Slide 54: NS002 Achieved Higher Absorption than EpiPen in Critical Therapeutic Window
NS002 Achieved Higher Absorption than EpiPen® in Critical Therapeutic Window Comparison of AUC at 2.5-240 minutes 1000.0 100.0 pg/mL*hr 10.0 7.1 4.3 A. NAC + IN spray Geometric mean B. EpiPen Geometric mean 2.0 C. IN spray, normal conditions Geometric mean 1.0 AUC0-2.5min AUC0-5min AUC0-10min AUC0-2
Slide 55: More Subjects Achieved Epinephrine Threshold with NS002 compared to EpiPen
More Subjects Achieved Epinephrine Threshold with NS002 compared to EpiPen® Proportion (%) who reached 100pg/mL 110 100 95.7 95.7 96.3 95.7 91.3 92.6 92.6 88.9 90 Proprtion reached 100pg/mL (%) 87.5 87.5 80 77.8 83.3 70 60.9 66.7 60 50 40 30 33.3 20 10 0 0 2.5 5 7.5 10 15 Time (min.) A. NAC + IN spr
Slide 56: Subject Achieving Epinephrine Threshold with Neffy
Subject Achieving Epinephrine Threshold with Neffy* Time to reach 100 pg/mL (minutes) median Single dose Double dose ARS “Neffy" ARS “Neffy*" x2 9 7-9 Subjects who reached 100 pg/ml within 60 minutes Single dose Double dose Time ARS “Neffy*" x2 ARS “Neffy*" (minutes) L/R R/R 5 18% 25% 20% 10 55% 55%
Slide 57: NS002 Pharmacodynamic Response Tracks EpiPen and Kept Within Normal Limits
NS002 Pharmacodynamic Response Tracks EpiPen® and Kept Within Normal Limits Median change from baseline - Systolic blood pressure (Single dose) 20 15 A. NAC+ Nasus 4mg B. EpiPen C. Nasus 4mg Baseline mm Hg (median): Median change (mm Hg) 10 NAC+Nasus x1 EpiPen Nasus x1 5 0 119 114 114 0 20 40 60 80
Slide 58: NS002 Pharmacodynamic Response Tracks EpiPen Cont.
NS002 Pharmacodynamic Response Tracks EpiPen® and Kept Within Normal Limits Cont. Median change from baseline- Heart rate (Single dose) 20 A. NAC+ Nasus 4mg B. EpiPen C. Nasus 4mg Baseline BPM (median): HR Median change (BPM) 15 10 NAC+Nasus x1 EpiPen Nasus x1 5 0 76 75 73 0 20 40 60 80 100 120 -5 -
Slide 59: Repeat Dosing Continues to Demonstrate Faster, Higher and Sustained Absorption
Repeat Dosing Continues to Demonstrate Faster, Higher and Sustained Absorption in a Dose Proportional Manner Normal conditions: NAC conditions: Geometric mean+SE, 0.5hr Geometric mean+SE, 0.5hr 1200 1000 D. EpiPen * 2 (L/R) D. EpiPen * 2 (L/R) 900 E1. IN * 2 (L/L), normal conditions 1000 F1. NAC + I
Slide 60: NS002 Repeated Dosing vs. EpiPen: Higher Cmax, Shorter Tmax and T100
NS002 Repeated Dosing vs. EpiPen©: Higher Cmax, Shorter Tmax and T100 Cmax (pg/mL) Tmax (min.) Geometric mean median 1400 25 1200 1087.93 20 19.2 19.2 1000 923.13 16.8 879.26 15.6 831.47 817.32 Cmax (pg/mL) Time (min.) 15 13.2 800 600 10 400 5 200 0 0 D. EpiPen * 2 (L/R) E1. IN * 2 (L/L), E2. IN * 2
Slide 61: More Subjects Achieve Epinephrine Threshold with NS002 Compared EpiPen
More Subjects Achieve Epinephrine Threshold with NS002 Compared EpiPen® Time to reach 100 pg/mL (minutes) median Single dose Double dose EpiPen® Nasus x1 Nasus x2 EpiPen® x2 (Nasus study) 1.0 3.1 0.6-0.9 2.7 Subjects who reached 100 pg/ml within 60 minutes Single dose Double dose Time EpiPen® EpiPen
Slide 62: NS002 Repeat Dosing Achieved Higher Absorption vs. EpiPen in Critical Therapeutic Window
NS002 Repeat Dosing Achieved Higher Absorption vs. EpiPen® in Critical Therapeutic Window AUC during first 10 minutes AUC at 20 and 30 minutes 60 350 300 50 250 40 AUC pg/ml*hr AUC pg/ml*hr 200 30 150 20 100 10 50 0 0 AUC0-2.5min AUC0-5min AUC0-10min AUC0-20min AUC0-30min D. EpiPen * 2 (L/R) Geometr
Slide 63: NS002 Repeat Dosing Tracks EpiPen and Kept Within Normal Limits
NS002 Repeat Dosing Tracks EpiPen® and Kept Within Normal Limits Median change from baseline - Systolic blood pressure (Normal conditions) 30 D. EpiPen x2 (L/R) E1. IN x 2 (L/L) E2. E2. IN x 2 (L/R) normal conditions normal conditions Baseline mm Hg (median): Median change (mm Hg) 20 Nasus x 2 EpiPe
Slide 64: NS002 Repeat Dosing Tracks EpiPen and Kept Within Normal Limits Cont.
NS002 Repeat Dosing Tracks EpiPen® and Kept Within Normal Limits Cont. Median Change from baseline- Diastolic blood pressure (Normal conditions) 30 D. EpiPen x2 (L/R) E1. IN x 2 (L/L) E2. E2. IN x 2 (L/R) Change from baseline (mm Hg) normal conditions normal conditions Baseline mm Hg (median): 20 Na
Slide 65: NS002 Repeat Dosing Tracks EpiPen and Kept Within Normal Limits Cont.
NS002 Repeat Dosing Tracks EpiPen® and Kept Within Normal Limits Cont. Median change from baseline- Heart rate (Normal conditions) 30 D. EpiPen x2 (L/R) E1. IN x 2 (L/L) E2. E2. IN x 2 (L/R) normal conditions normal conditions Baseline BPM (median): HR Median change (BPM) 20 Nasus x 2 EpiPen x2 Nasu
Slide 66: NS001: Intranasal Naloxone
NS001: INTRANASAL NALOXONE 66
Slide 67: Pivotal Study Validated the Superiority of Powder over Liquid
Pivotal Study Validated the Superiority of Powder over Liquid, Demonstrating Nasax Platform Delivers Naloxone Faster Compared to Narcan® In our phase 3 (n=42) intranasal naloxone study (NS-001), our formulation provided faster delivery and higher mean absorption of naloxone compared to Narcan® The r